Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

McMaster University

$105,000.00

Understanding the role of dysregulated synapsin II in the pathophysiology of schizophrenia

EF 2008-09

Résumé
Affecting roughly 1% of the global population, schizophrenia is one of the most debilitating life long mental illnesses, costing an estimated $2.35 billion in treatment and management per year in Canada alone. Furthermore, current therapeutic treatment for schizophrenia through the use of antipsychotic drugs is associated with a myriad of undesirable side effects. Recent research on the underlying mechanisms of schizophrenia has focused on changes at the synapses of neurons, the regions through which nerve cells communicate with one another. The protein synapsin II has become a popular candidate potentially responsible for such synaptic changes. Decreases in synapsin II concentrations can be found in the prefrontal cortices of subjects with schizophrenia, indicating an underlying imbalance in synapsin II regulation. However, it has not been confirmed whether reductions in synapsin II are a causative factor in the development of schizophrenia or rather result from this disease. Research from my Master's studies has provided evidence that decreases in synapsin II may be responsible for the development of schizophrenic-like behaviors in a novel animal model. Furthermore, treatment with antipsychotic drugs can reverse behavioral changes induced by decreases in synapsin II, suggesting that the mechanisms of these drugs may involve synapsin signaling pathways. The goal of my research is to understand how decreases in synapsin II levels can interrupt dopamine and glutamate signaling, two neurotransmitters that are known to be imbalanced in the schizophrenic brain. Currently there is no cure for schizophrenia, and as previously mentioned antipsychotic drug treatment results in unacceptable side effects due to the manner in which these drugs interact with their target receptors. Understanding the role of synapsin II in schizophrenia may ultimately lead to new and more effective drug treatments, allowing these basic scientific results to translate to a clinical setting.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
184426
Name
Dyck Bailey A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Understanding the role of dysregulated synapsin II in the pathophysiology of schizophrenia
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Antipsychotic Drugs; Dopamine; Glutamate; Locomotor Activity; Prepulse Inhibition; Primary Cell Cultures; Schizophrenia; Social Interaction; Synapsin Ii
Abstract
Affecting roughly 1% of the global population, schizophrenia is one of the most debilitating life long mental illnesses, costing an estimated $2.35 billion in treatment and management per year in Canada alone. Furthermore, current therapeutic treatment for schizophrenia through the use of antipsychotic drugs is associated with a myriad of undesirable side effects. Recent research on the underlying mechanisms of schizophrenia has focused on changes at the synapses of neurons, the regions through which nerve cells communicate with one another. The protein synapsin II has become a popular candidate potentially responsible for such synaptic changes. Decreases in synapsin II concentrations can be found in the prefrontal cortices of subjects with schizophrenia, indicating an underlying imbalance in synapsin II regulation. However, it has not been confirmed whether reductions in synapsin II are a causative factor in the development of schizophrenia or rather result from this disease. Research from my Master's studies has provided evidence that decreases in synapsin II may be responsible for the development of schizophrenic-like behaviors in a novel animal model. Furthermore, treatment with antipsychotic drugs can reverse behavioral changes induced by decreases in synapsin II, suggesting that the mechanisms of these drugs may involve synapsin signaling pathways. The goal of my research is to understand how decreases in synapsin II levels can interrupt dopamine and glutamate signaling, two neurotransmitters that are known to be imbalanced in the schizophrenic brain. Currently there is no cure for schizophrenia, and as previously mentioned antipsychotic drug treatment results in unacceptable side effects due to the manner in which these drugs interact with their target receptors. Understanding the role of synapsin II in schizophrenia may ultimately lead to new and more effective drug treatments, allowing these basic scientific results to translate to a clinical setting.
Competitiondate
200810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Dyck, Bailey A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~